2.56
+0.21(+8.94%)
Currency In USD
| Previous Close | 2.35 |
| Open | 2.42 |
| Day High | 2.7 |
| Day Low | 2.08 |
| 52-Week High | 778 |
| 52-Week Low | 1.74 |
| Volume | 1.23M |
| Average Volume | 1.23M |
| Market Cap | 7.87M |
| PE | -0.03 |
| EPS | -88.92 |
| Moving Average 50 Days | 8.13 |
| Moving Average 200 Days | 77.74 |
| Change | 0.21 |
Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada
GlobeNewswire Inc.
16 hours ago
NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) announced today that it completed a strategic reorganizati
Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada
GlobeNewswire Inc.
Yesterday at 12:30 PM GMT
NEWPORT BEACH, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly known as Elevai Labs Inc.) (Nasdaq: ELAB) (before and after the redomestication, the “Company” or “we”) announced today that it plans to effectuate a strategic re
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation
GlobeNewswire Inc.
Dec 09, 2024 1:00 PM GMT
EL-22, a first-in-class myostatin asset, is being developed as a potential combination therapy with GLP-1 receptor agonists for obesity. It aims to address muscle loss, a common side effect of rapid weight loss from GLP-1-based treatments, by preserv